These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 22175130

  • 1. [Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 2. Salazosulfapyridine].
    Kawai S.
    Nihon Naika Gakkai Zasshi; 2011 Oct 10; 100(10):2910-7. PubMed ID: 22175130
    [No Abstract] [Full Text] [Related]

  • 2. [Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 1. Methotrexate].
    Suzuki Y, Chinen N.
    Nihon Naika Gakkai Zasshi; 2011 Oct 10; 100(10):2902-9. PubMed ID: 22175129
    [No Abstract] [Full Text] [Related]

  • 3. Use of sulfasalazine in rheumatic diseases.
    Fuchs HA.
    Bull Rheum Dis; 1997 Nov 10; 46(7):3-4. PubMed ID: 9366125
    [No Abstract] [Full Text] [Related]

  • 4. [A survey of the doses of methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis].
    Kawai S, Ochi T, Kondo H, Nishioka K, Nobuyuki N, Yoshino S.
    Ryumachi; 2002 Feb 10; 42(1):76-9. PubMed ID: 11925910
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of iguratimod vs. salazosulfapyridine as the first-line csDMARD for rheumatoid arthritis.
    Nozaki Y, Inoue A, Kinoshita K, Funauchi M, Matsumura I.
    Mod Rheumatol; 2020 Mar 10; 30(2):249-258. PubMed ID: 30676812
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study.
    Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA, Steven M, Zoma A, Morrison E, Sambrook M, Wui Poon F, Hampson R, McDonald F, Tierney A, Henderson N, Ford I.
    Ann Rheum Dis; 2007 Feb 10; 66(2):235-41. PubMed ID: 16926184
    [Abstract] [Full Text] [Related]

  • 7. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.
    Rains CP, Noble S, Faulds D.
    Drugs; 1995 Jul 10; 50(1):137-56. PubMed ID: 7588084
    [Abstract] [Full Text] [Related]

  • 8. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents].
    Schnabel A, Gross WL.
    Dtsch Med Wochenschr; 2003 Jan 24; 128(4):147-9. PubMed ID: 12589584
    [No Abstract] [Full Text] [Related]

  • 9. A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine.
    Wojciechowski J, Wiese MD, Proudman SM, Foster DJ, Upton RN.
    Br J Clin Pharmacol; 2015 May 24; 79(5):777-88. PubMed ID: 25394211
    [Abstract] [Full Text] [Related]

  • 10. [Rheumatoid arthritis: progress in diagnosis and treatment. Topics: IV. Treatment; 2. Antirheumatic agents, 1) non-biologic agents].
    Tamura N.
    Nihon Naika Gakkai Zasshi; 2012 Oct 10; 101(10):2873-9. PubMed ID: 23214096
    [No Abstract] [Full Text] [Related]

  • 11. [Methotrexate and salazosulfapyridine in the long-term treatment of rheumatoid arthritis].
    Ichikawa Y, Shinozawa T, Yoshida T, Kameda H, Suzuki Y, Kawai S, Yamada H, Matsuda T.
    Ryumachi; 1995 Aug 10; 35(4):663-70. PubMed ID: 7482063
    [Abstract] [Full Text] [Related]

  • 12. Current concepts in the management of rheumatoid arthritis.
    Murphy NG.
    Del Med J; 1992 Apr 10; 64(4):257-64. PubMed ID: 1352263
    [No Abstract] [Full Text] [Related]

  • 13. [Three joints swollen, blood sedimentation increased. Methotrexate to be given immediately?].
    Burmester GR.
    MMW Fortschr Med; 2004 Sep 09; 146(37):10. PubMed ID: 15887693
    [No Abstract] [Full Text] [Related]

  • 14. Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease.
    Borg AA.
    Br J Rheumatol; 1995 Nov 09; 34(11):1097-8. PubMed ID: 8542218
    [No Abstract] [Full Text] [Related]

  • 15. Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis.
    Haibel H, Specker C.
    Clin Exp Rheumatol; 2009 Nov 09; 27(4 Suppl 55):S159-63. PubMed ID: 19822065
    [Abstract] [Full Text] [Related]

  • 16. Treatment of rheumatoid arthritis.
    Schinagl EF, Strauss PC.
    N Engl J Med; 1996 Sep 12; 335(11):822; author reply 822-3. PubMed ID: 8778594
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. How do second-line agents work?
    Choy E, Kingsley G.
    Br Med Bull; 1995 Apr 12; 51(2):472-92. PubMed ID: 7552077
    [Abstract] [Full Text] [Related]

  • 19. [Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis].
    Taniguchi A, Urano W, Tanaka E, Kamatani N.
    Nihon Rinsho; 2007 Feb 12; 65(2):371-9. PubMed ID: 17302286
    [Abstract] [Full Text] [Related]

  • 20. Treatment of rheumatoid arthritis.
    Zurier RB, DeMarco DM, Liu NY.
    N Engl J Med; 1996 Sep 12; 335(11):822; author reply 822-3. PubMed ID: 8778595
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.